MX383971B - Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. - Google Patents

Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan.

Info

Publication number
MX383971B
MX383971B MX2017012506A MX2017012506A MX383971B MX 383971 B MX383971 B MX 383971B MX 2017012506 A MX2017012506 A MX 2017012506A MX 2017012506 A MX2017012506 A MX 2017012506A MX 383971 B MX383971 B MX 383971B
Authority
MX
Mexico
Prior art keywords
fusion protein
tissue
vegf
eye diseases
fused
Prior art date
Application number
MX2017012506A
Other languages
English (en)
Other versions
MX2017012506A (es
Inventor
Hyei Yoon Jung
Hyuk Sang Kwon
Jae- Hoon KANG
Seok Woo Yang
Seong Beom Kim
Original Assignee
Ildong Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharm Co Ltd filed Critical Ildong Pharm Co Ltd
Publication of MX2017012506A publication Critical patent/MX2017012506A/es
Publication of MX383971B publication Critical patent/MX383971B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica caracterizada porque, cuando se usa en prevención y/o tratamiento de una enfermedad del ojo inducida por neovascularización a través de administración intraocular, comprende, como un ingrediente activo, una proteína de fusión en donde un péptido que penetra el tejido está fusionado a un agente del factor de crecimiento endotelial antivascular (anti-VEGF), en donde el péptido que penetra el tejido comprende cualquier secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID NO: 1 a 7, en donde el agente anti factor de crecimiento endotelial vascular (anti-VEGF) se selecciona del grupo que consiste en renibizumab, bevacizumb, aflibercept, conbercept, r84, CT01, DOM15-10-11 DOM15-26-593, PRS-050, CT -322 ESBA903, EPI-0030, y un mutante de ranibizumab que consiste en una dadena ligera rpresentada por SEQ ID NO: 8 y una cadena pesada representada por SEQ ID NO: 10.
MX2017012506A 2015-03-31 2016-03-30 Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. MX383971B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150045684 2015-03-31
PCT/KR2016/003254 WO2016159652A1 (ko) 2015-03-31 2016-03-30 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
MX2017012506A MX2017012506A (es) 2018-06-27
MX383971B true MX383971B (es) 2025-03-14

Family

ID=57004803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012506A MX383971B (es) 2015-03-31 2016-03-30 Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan.

Country Status (11)

Country Link
US (2) US11052130B2 (es)
EP (2) EP3278810A4 (es)
JP (1) JP6836512B2 (es)
KR (1) KR101846306B1 (es)
CN (1) CN108348572B (es)
AU (1) AU2016241499B2 (es)
BR (1) BR112017020948A2 (es)
CA (1) CA2981145C (es)
MX (1) MX383971B (es)
RU (1) RU2712623C2 (es)
WO (1) WO2016159652A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561707B2 (en) 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
BR112017020948A2 (pt) 2015-03-31 2018-07-10 Ildong Pharm Co., Ltd. composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017130194A1 (en) * 2016-01-25 2017-08-03 Rappaport Family Institute For Research In The Medical Sciences Semaphorin 3c variants, compositions comprising said variants and methods of use thereof in treating eye diseases
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
KR20210021299A (ko) * 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
EP3808842A4 (en) * 2018-06-14 2022-11-23 Avixgen Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEVERE COMPLEX IMMUNE DEFICIENCY WITH A CELL-PERFORMING PEPTIDE AND ADENOSINDEAMINASE FUSION PROTEIN
US20210068733A1 (en) * 2019-09-06 2021-03-11 United States Government As Represented By The Department Of Veterans Affairs Methods and systems for self-administered measurement of critical flicker frequency (cff)
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN113384715B (zh) * 2021-06-03 2023-08-04 上海市第十人民医院 一种含有细胞穿透肽融合蛋白的抗vegf药物及其制备方法和应用
WO2023280157A1 (zh) * 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
WO2024144099A1 (ko) * 2022-12-27 2024-07-04 주식회사 넥스세라 안구 질환 치료를 위한 효율적인 약물 전달 플랫폼
CN116785440A (zh) * 2023-08-09 2023-09-22 天津医科大学总医院 Sema4D抑制剂在制备预防和/或治疗脉络膜新生血管药物中的应用
CN118108862B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗血管新生的融合蛋白及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
US20070071756A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901301A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Полипептиды, вариабельные домены антител и антагонисты
CN101951925A (zh) * 2008-02-20 2011-01-19 建新公司 血管发生抑制
FI121959B (fi) * 2008-05-09 2011-06-30 Pirjo Laakkonen Aivokasvaimiin hakeutuva peptidi
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
AU2010250452B2 (en) * 2009-05-20 2014-06-05 Toray Industries, Inc. Cell membrane-permeable peptides
BRPI1015424B1 (pt) * 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
KR20130096731A (ko) * 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
EP3646880A1 (en) 2012-05-07 2020-05-06 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JP6391676B2 (ja) 2013-05-23 2018-09-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ニューロピリンに特異的な腫瘍浸透性ペプチド及びこのペプチドが融合された融合タンパク質
CN105308844B (zh) 2013-09-19 2018-05-22 飞利浦照明控股有限公司 具有连续输出调节范围的紧凑功率转换设备
KR102157618B1 (ko) 2013-10-21 2020-09-18 주식회사 아이티엘 서빙셀별로 듀플렉스 방식을 달리하는 무선 통신 시스템에서 통신을 수행하는 장치 및 그 방법
BR112017020948A2 (pt) 2015-03-31 2018-07-10 Ildong Pharm Co., Ltd. composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão

Also Published As

Publication number Publication date
AU2016241499B2 (en) 2020-12-17
WO2016159652A1 (ko) 2016-10-06
JP2018515435A (ja) 2018-06-14
US11738064B2 (en) 2023-08-29
CA2981145C (en) 2021-05-11
US20210220436A1 (en) 2021-07-22
MX2017012506A (es) 2018-06-27
BR112017020948A2 (pt) 2018-07-10
EP3278810A1 (en) 2018-02-07
AU2016241499A1 (en) 2017-11-09
KR20160117329A (ko) 2016-10-10
KR101846306B1 (ko) 2018-05-18
RU2017137735A (ru) 2019-04-30
RU2712623C2 (ru) 2020-01-30
JP6836512B2 (ja) 2021-03-03
CN108348572A (zh) 2018-07-31
RU2017137735A3 (es) 2019-09-11
CN108348572B (zh) 2021-06-29
US20180133288A1 (en) 2018-05-17
CA2981145A1 (en) 2016-10-06
EP3278810A4 (en) 2018-11-21
US11052130B2 (en) 2021-07-06
EP3973977A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
MX383971B (es) Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan.
US20220313770A1 (en) Immunotherapy for angiogenic disease
El Sanharawi et al. Protein delivery for retinal diseases: from basic considerations to clinical applications
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
TN2013000493A1 (en) Stable liquid formulation of etanercept
JP2016514132A5 (es)
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
FI4017871T3 (fi) Alfa-sarkoglykaaniin liittyvä adeno-assosioidun virusvektorin antaminen ja lihasdystrofian hoito
JP2016516016A5 (es)
US20190225660A1 (en) Method of treating and preventing ocular angiogenesis
RU2020129180A (ru) Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы
JP2022062153A (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
RU2019109154A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ТЕРАПИИ ДЕФИЦИТА ГОРМОНА РОСТА, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК hGH
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
US11793889B2 (en) Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases
RU2021120837A (ru) Состав на основе раствора белка, содержащий антитело к vegf в высокой концентрации
WO2023069993A1 (en) Encapsulated cells expressing il-2 and uses thereof
CN103788179B (zh) 多肽小分子及其在制备防治膀胱过度活跃药物中的应用
HK1245149A1 (en) Wt1 immunotherapy for intraocular angiogenic disease
RU2020114917A (ru) Способ лечения болезней глаз